Table 2.

Summary of clinical trials for cancer immunotherapy targeting GPC3.

Trial	Patients	ID
A randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous GC33 at 1,600 mg Q2W in previously treated patients with unresectable advanced or metastatic HCC	Histologically confirmed HCC	NCT 01507168
A phase I dose escalation and cohort expansion study of ERY974, an anti-GPC3/CD3 bispecific antibody, in patients with advanced solid tumors	Patients with GPC3-positive advanced solid tumors not amenable to standard therapy or for which standard therapy was not available or not indicated	NCT 02748837
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells in Chinese patients with refractory or relapsed GPC3 + HCC	Patients with GPC3-positive HCC	NCT 02395250
Glypican 3-specific chimeric antigen receptor expressing T cells as immunotherapy for patients with HCC	Patients with GPC3-positive HCC	NCT 02905188

GPC3, glypican-3; HCC, hepatocellular carcinoma.